- Home
- CURX vs BNGO Comparison
CURX vs BNGO Comparison
Compare CURX & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURX | BNGO |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 11.6M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CURX | BNGO |
|---|---|---|
| Price | $0.48 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | ★ 5.4M | 257.0K |
| Earning Date | 09-09-2025 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | N/A | $25.49 |
| Revenue Next Year | N/A | $48.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.26 | $1.06 |
| 52 Week High | $9.18 | $5.50 |
Technical Indicators
Market Signals| Indicator | CURX | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 47.01 |
| Support Level | $0.37 | $1.07 |
| Resistance Level | $0.51 | $1.18 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.18 | 13.51 |
Price Performance
Historical ComparisonAbout CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.